p-ERK 1/2 Antibody (pT202/pY204.22A): sc-136521

p-ERK 1/2 Antibody (pT202/pY204.22A) is a mouse monoclonal IgG1 kappa light chain antibody that detects p-ERK 1/2 in mouse, rat, and human samples through applications such as western blotting (WB), immunofluorescence (IF), and immunohistochemistry with paraffin-embedded sections (IHCP). p-ERK 1/2 monoclonal antibody (pT202/pY204.22A) is available in both conjugated and non-conjugated forms, providing flexibility for various experimental needs. ERK 1 and ERK 2 play a crucial role in mediating signal transduction pathways activated by growth factors, hormones, and neurotransmitters, which are essential for cellular responses such as proliferation, differentiation, and survival. These proteins are located primarily in the cytoplasm but can translocate to the nucleus upon activation, where they influence gene expression. Dual phosphorylation of ERK 1 and ERK 2 at specific threonine and tyrosine residues is vital for activation, leading to conformational changes that allow phosphorylation of downstream targets. A characteristic Thr-Glu-Tyr motif maintains structural integrity of ERK proteins, and activation is tightly regulated by upstream kinases, including MAP kinase kinase (MEK) and Raf-1. Understanding p-ERK 1/2 dynamics is critical for elucidating mechanisms of various signaling pathways and their implications in diseases such as cancer, where aberrant MAPK signaling is often observed. anti-p-ERK 1/2 antibody (pT202/pY204.22A) provides a robust tool for examining dual phosphorylation of ERK 1/2 at Thr 202 and Tyr 204, a critical event that drives activation and downstream effects within the MAPK signaling pathway.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

p-ERK 1/2 Antibody (pT202/pY204.22A) References:

1. The regulation of ERK and p-ERK expression by cisplatin and sorafenib in gastric cancer cells.  |  Tao, C., et al. 2014. Gene. 552: 106-15. PMID: 25219752
2. Activation of the SphK1/ERK/p-ERK pathway promotes autophagy in colon cancer cells.  |  Xu, C., et al. 2018. Oncol Lett. 15: 9719-9724. PMID: 29928348
3. Ambroxol attenuates cisplatin-induced hepatotoxicity and nephrotoxicity via inhibition of p-JNK/p-ERK.  |  Bishr, A., et al. 2019. Can J Physiol Pharmacol. 97: 55-64. PMID: 30383980
4. P-AKT2/SPK1 (P-SPK1) and P-MEK/P-ERK cell signaling pathways are involved in LPS-induced macrophage migration.  |  Lei, Y., et al. 2019. Am J Transl Res. 11: 2725-2741. PMID: 31217849
5. IL-6/p-BTK/p-ERK signaling mediates calcium phosphate-induced pruritus.  |  Keshari, S., et al. 2019. FASEB J. 33: 12036-12046. PMID: 31365830
6. Diabetes Mellitus Promotes Smooth Muscle Cell Proliferation in Mouse Ureteral Tissue through the P-ERK/P-JNK/VEGF/PKC Signaling Pathway.  |  Choi, T., et al. 2021. Medicina (Kaunas). 57: PMID: 34206139
7. Correlation between urinary KIM-1 and kidney protein expression of p-ERK following damage in rats exposed to gentamicin or lead acetate.  |  Ruiz-Ramirez, C., et al. 2021. J Biochem Mol Toxicol. 35: e22875. PMID: 34350654
8. p-mTOR, p-ERK and PTEN Expression in Tumor Biopsies and Organoids as Predictive Biomarkers for Patients with HPV Negative Head and Neck Cancer.  |  de Kort, WWB., et al. 2023. Head Neck Pathol. 17: 697-707. PMID: 37486536
9. PAK4 inhibition significantly potentiates Gemcitabine activity in PDAC cells via inhibition of Wnt/β-catenin, p-ERK/MAPK and p-AKT/PI3K pathways.  |  Samant, C., et al. 2023. Biochem Biophys Rep. 35: 101544. PMID: 37720313
10. BRAFV600E/p-ERK/p-DRP1(Ser616) Promotes Tumor Progression and Reprogramming of Glucose Metabolism in Papillary Thyroid Cancer.  |  Wen, SS., et al. 2024. Thyroid. 34: 1246-1259. PMID: 39162997

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-p-ERK 1/2 Antibody (pT202/pY204.22A) has 131 citations in a variety of scientific publications.

Primary antibodies like Anti-p-ERK 1/2 Antibody (pT202/pY204.22A) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

p-ERK 1/2 Antibody (pT202/pY204.22A) Specifications

Alternate Product Name: p44/42 MAPK

Product Clone Name: pT202/pY204.22A

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: Thr 203/Tyr 205

Epitope Target: ERK 1

Epitope Species: rat

Product Reactivity/Detection: Thr 202 and Tyr 204 dually phosphorylated ERK 1 of human origin, correspondingly Thr 203 and Tyr 205 dually phosphorylated ERK 1 of mouse and rat origin; and Thr 185 and Tyr 187 dually phosphorylated ERK 2 of human origin, correspondingly Thr 183 and Tyr 185 dually phosphorylated ERK 2 of mouse and rat origin

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IF, IHC(P)

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 131 citations in various scientific publications

Available Conjugates/Forms for p-ERK 1/2 Antibody (pT202/pY204.22A): AC: Agarose, HRP: Horseradish Peroxidase

The preferred p-ERK antibody is p-ERK Antibody (E-4): sc-7383.